Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Werter IM, Huijts CM, Lougheed SM, Hamberg P, Polee MB, Tascilar M, Los M, Haanen JBAG, Helgason HH, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Feb 11. doi: 10.1007/s00262-019-02313-z. [Epub ahead of print]

PMID:
30756132
2.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, Blank CU, Hospers GAP, Fehrmann RSN.

Oncoimmunology. 2019 Jan 3;8(3):1558664. doi: 10.1080/2162402X.2018.1558664. eCollection 2019.

3.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Jan 17. doi: 10.1007/s00262-018-2288-8. [Epub ahead of print]

PMID:
30652208
4.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I.

Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27.

PMID:
30595452
5.

NKG2A, a New Kid on the Immune Checkpoint Block.

Haanen JB, Cerundolo V.

Cell. 2018 Dec 13;175(7):1720-1722. doi: 10.1016/j.cell.2018.11.048.

PMID:
30550781
6.

Characterisation of rare haematological immune-related toxicities.

Haanen JB, Peters S.

Lancet Haematol. 2019 Jan;6(1):e10-e11. doi: 10.1016/S2352-3026(18)30180-7. Epub 2018 Dec 4. No abstract available.

PMID:
30528136
7.

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, Kluin RJC, Snaebjornsson P, Milne K, Nelson BH, Zijlmans H, Kenter G, Voest EE, Haanen JBAG, Schumacher TN.

Nat Med. 2019 Jan;25(1):89-94. doi: 10.1038/s41591-018-0266-5. Epub 2018 Dec 3.

PMID:
30510250
8.

Adoptive cellular therapies: the current landscape.

Rohaan MW, Wilgenhof S, Haanen JBAG.

Virchows Arch. 2018 Nov 23. doi: 10.1007/s00428-018-2484-0. [Epub ahead of print] Review.

PMID:
30470934
9.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D.

Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13.

PMID:
30425107
10.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP.

Cancer Immunol Res. 2019 Jan;7(1):77-85. doi: 10.1158/2326-6066.CIR-18-0136. Epub 2018 Nov 13.

PMID:
30425105
11.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Feb;68(2):319-329. doi: 10.1007/s00262-018-2248-3. Epub 2018 Nov 9.

PMID:
30413837
12.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Lindenberg MA, Retèl VP, van den Berg JH, Geukes Foppen MH, Haanen JB, van Harten WH.

J Immunother. 2018 Nov/Dec;41(9):413-425. doi: 10.1097/CJI.0000000000000245.

13.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN.

Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.

PMID:
30297911
14.

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG.

J Immunother Cancer. 2018 Oct 3;6(1):102. doi: 10.1186/s40425-018-0391-1. Review.

15.

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

Retèl VP, Steuten LMG, Geukes Foppen MH, Mewes JC, Lindenberg MA, Haanen JBAG, van Harten WH.

BMC Cancer. 2018 Sep 15;18(1):895. doi: 10.1186/s12885-018-4788-5.

16.

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM.

Ned Tijdschr Geneeskd. 2018 Jun 15;162. pii: D2420. Dutch.

PMID:
30040270
17.

Questions asked in the everyday practice: immune checkpoint inhibitors.

Haanen JBAG.

ESMO Open. 2018 Jun 23;3(4):e000395. doi: 10.1136/esmoopen-2018-000395. eCollection 2018. No abstract available.

18.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv264-iv266. doi: 10.1093/annonc/mdy162. No abstract available.

PMID:
29917046
19.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM.

Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453.

PMID:
29750749
20.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
21.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
22.

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG.

ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018. Review.

23.

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.

Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.

PMID:
29356790
24.

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

Rozeman EA, Dekker TJA, Haanen JBAG, Blank CU.

Am J Clin Dermatol. 2018 Jun;19(3):303-317. doi: 10.1007/s40257-017-0325-6. Review.

PMID:
29164492
25.

Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Brouwer NJ, Haanen JBAG, Jager MJ.

Ocul Oncol Pathol. 2017 Sep;3(3):188-192. doi: 10.1159/000455150. Epub 2017 Feb 2.

26.

Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.

Smit EF, Haanen JBAG.

J Clin Oncol. 2017 Dec 1;35(34):3794-3795. doi: 10.1200/JCO.2017.74.5141. Epub 2017 Oct 10. No abstract available.

PMID:
29016228
27.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA.

Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.

28.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group.

BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5.

29.

Converting Cold into Hot Tumors by Combining Immunotherapies.

Haanen JBAG.

Cell. 2017 Sep 7;170(6):1055-1056. doi: 10.1016/j.cell.2017.08.031.

30.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225. No abstract available.

PMID:
28881921
31.

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

de Bruijn RE, Kuusk T, Noe AP, Blank CU, Haanen JBAG, Hendricksen K, Horenblas S, Bex A.

Urology. 2017 Nov;109:127-133. doi: 10.1016/j.urology.2017.06.048. Epub 2017 Aug 2.

PMID:
28780300
32.

Fixed Dosing of Monoclonal Antibodies in Oncology.

Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH.

Oncologist. 2017 Oct;22(10):1212-1221. doi: 10.1634/theoncologist.2017-0167. Epub 2017 Jul 28. Review.

33.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
34.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.

35.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Samuels S, Marijne Heeren A, Zijlmans HJMAA, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen JBAG, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2017 Sep;66(9):1163-1173. doi: 10.1007/s00262-017-2006-y. Epub 2017 Apr 27.

PMID:
28451790
36.

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

Meerveld-Eggink A, Rozeman EA, Lalezari F, van Thienen JV, Haanen JBAG, Blank CU.

Ann Oncol. 2017 Apr 1;28(4):862-867. doi: 10.1093/annonc/mdw692.

PMID:
28158487
37.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU.

Oncoimmunology. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016.

38.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

39.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
40.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
41.

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP, Fehrmann RSN.

J Natl Cancer Inst. 2016 Oct 13;109(1). doi: 10.1093/jnci/djw192. Print 2017 Jan.

42.

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, El Atmioui D, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192d. No abstract available.

PMID:
27711057
43.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

Boudewijns S, Koornstra RH, Westdorp H, Schreibelt G, van den Eertwegh AJ, Geukes Foppen MH, Haanen JB, de Vries IJ, Figdor CG, Bol KF, Gerritsen WR.

Oncoimmunology. 2016 Jun 17;5(8):e1201625. doi: 10.1080/2162402X.2016.1201625. eCollection 2016 Aug.

44.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS).

Oncology. 2016;91(5):267-273. Epub 2016 Aug 20.

PMID:
27544669
45.

(Neo)adjuvant systemic therapy for melanoma.

van Zeijl MC, van den Eertwegh AJ, Haanen JB, Wouters MW.

Eur J Surg Oncol. 2017 Mar;43(3):534-543. doi: 10.1016/j.ejso.2016.07.001. Epub 2016 Jul 11. Review.

PMID:
27453302
46.

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

Steenbruggen TG, van den Heuvel MM, Blank CU, van Dieren JM, Haanen JB, Kok M.

Ned Tijdschr Geneeskd. 2016;160:A9873. Dutch.

PMID:
27438388
47.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH.

J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29. No abstract available.

PMID:
27365214
48.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
49.

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJC, Sun C, Voest EE, Ju YS, Schumacher TNM, Altelaar AFM, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS.

Cell Rep. 2016 Jun 28;16(1):263-277. doi: 10.1016/j.celrep.2016.05.064. Epub 2016 Jun 16.

50.

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

De Groot S, Sleijfer S, Redekop WK, Oosterwijk E, Haanen JB, Kiemeney LA, Uyl-de Groot CA.

BMC Cancer. 2016 Jun 11;16:364. doi: 10.1186/s12885-016-2395-x.

Supplemental Content

Loading ...
Support Center